Inbrain Neuroelectronics invents neuroelectronic therapies to address neural disorders. The company utilizes graphene technology to develop high-resolution brain-computer interfaces and implantable neuroprocessors, focusing on enhancing patient outcomes through personalized therapy.

Inbrain Neuroelectronics

INBRAIN Neuroelectronics | 16,531 followers on LinkedIn. High density and high resolution graphene intelligent neural systems for BCI therapeutics *FDA Breakthrough Designation* | High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications. *FDA breakthrough Designation* Pioneering Precision Neurology

Professor of Business Administration (Marketing) - IESE Business School

Mario Capizzani

Medical Device Development specialist

Marini Witjes

Head of embedded engineering

Martijn Hazenberg

Senior Embedded Engineer en INBRAIN Neuroelectronics

Daniel Martin

INBRAIN Neuroelectronics

Thanks Nasdaq for celebrating our $50M Series B financing led by imec.xpand . 🔥🔥🔥 New investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and AVANÇSA , and existing investors Asabys Partners , Aliath Bioventures and Vsquared Ventures also participated, bringing the total amount raised since inception to $68 million. The company’s technology utilizes the unique properties of #graphene , a Nobel Prize-winning material known for its strength, flexibility, and conductivity. Read our press release: https://lnkd.in/eBvGGr93 Watch CEO Carolina Aguilar on Bloomberg Television : https://lnkd.in/e9MJjaNh

Graphene implants decode the complexities of the human brain INBRAIN Neuroelectronics CEO Carolina Aguilar explains how new advances in BCI technology have the potential to diagnose and treat multiple brain conditions in real-time. #longevity #neurotech #graphene #BCI #brain

Longevity.Technology

Thanks Longevity.Technology for speaking with our CEO Carolina Aguilar about our recent updates! 🧠🧠 Using Parkinson’s disease as an example, Aguilar says that understanding how and where certain effects are triggered is key. By identifying the specific neural patterns and activity associated with different brain functions and dysfunctions, Inbrain’s technology can precisely decode the origins of symptoms. This allows the company to deliver targeted therapeutic interventions to treat the underlying neural issues. Read the article by Danny Sullivan : https://lnkd.in/e9amHBdG

Last Tuesday, INBRAIN Neuroelectronics had the opportunity to participate in the Neurotechnology's rapid evolution – What consequences for the EU regulatory landscape? hybrid event organised by The International Center for Future Generations - ICFG and hosted by @Euractiv. Javier Castillo , our Head of Quality and Regulatory participated in the discussion together with Antonia Mochan , Guilherme Maia de Oliveira Wood, Ricardo Chavarriaga , Arleen Salles , PhD, and Virginia Mahieu ! A great opportunity to understand the Neurotechnology governance and strategy in the EU as well as the rapidly evolving landscape globally.

Join us at Impact/Week for an exciting conversation on Revolutionizing Healthcare through Advanced Materials Our Managing Partner, Josep Ll. Sanfeliu , will be on stage with Jose Antonio Garrido , Vice Director at the Institut Català de Nanociència i Nanotecnologia (ICN2) and Co-Founder of INBRAIN Neuroelectronics . Together, they’ll explore how groundbreaking materials like graphene are shaping the future of neuroelectronic therapies and opening new frontiers in healthcare. 📍 Location: @Norrsken, Beach Lounge 📅 Date: November 6 🕑 Time: 2:10 pm – 2:40 pm Don’t miss this opportunity to gain insights into the latest advancements at the intersection of nanotechnology and healthcare innovation! #AsabysPartners #ImpactWeek #HealthcareInnovation #Nanotechnology #Graphene #Neuroelectronics

Asabys Partners

Thanks The Guardian and editor Robin McKie for following and reporting on our story The size of a postage stamp, the device is made of graphene, a material 200 times stronger than steel and only one atom thick. Graphene was invented 20 years ago by Manchester University scientists Andre Geim and Konstantin Novoselov, who later won the 2010 Nobel prize in physics for their research. Scientists have since been working to exploit the remarkable conductive properties of graphene in order to develop new electrical and magnetic sensors and other devices. However, the flexible brain chip – now being trialled at Salford Royal hospital – is being hailed as a medical first. “This is the first ever clinical trial to be performed anywhere in the world with a graphene-based medical device,” said one of the team’s leaders, Kostas Kostarelos , a professor of nanomedicine at Manchester. https://lnkd.in/dyayCRay

Ending this amazing week with winning the IGA2024 Graphene Product Innovation Award today! 🎉🎉🎉 Thank you to the International Graphene Association. “They have leveraged groundbreaking graphene technology to successfully conduct the world's first human trials for highly precise and minimally-invasive neuron detection and treatment solutions, driving innovation in brain-machine interfaces and neurological disorder therapies. Their remarkable achievements not only highlight the immense potential of graphene in the medical field but also offer unprecedented hope to neurological patients globally. Congratulations to Inbrain Neuroelectronics for winning the IGA 2024 Graphene Product Innovation Award for their newly developed graphene-based brain implant.” Thanks Stephan Roche for taking the prize on our behalf! More details about the event: http://www.grapchina.com/

HUGE UPDATE!🚨 INBRAIN Neuroelectronics has secured a $50 MILLION Series B financing round, led by imec.xpand . With this funding, they’ll accelerate the development and commercialisation of their BCI therapeutics through supporting ongoing clinical trials, team expansion and developing their AI-powered platform for the treatment of neurological-related diseases. They’re making absolute waves in the neurological space, read the full story here 👉 https://lnkd.in/eVwCvvzD

University of Manchester Innovation Factory

Our team in Business Insider España : https://lnkd.in/ewyffbY5

Thanks Longevity.Technology for covering our funding news! https://lnkd.in/e_vb_Zyf

Metric
Company Name	Inbrain Neuroelectronics
Symbol
MSH ID	COM:INBRAIN-NEUROELECTRONICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	ES
Stage
Employee Count
Website	inbrain-neuroelectronics.com
LinkedIn	inbrain-neuroelectronics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INBR

COM:INBRAIN-NEUROELECTRONICS

Inbrain Neuroelectronics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue